Overview

TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam

Status:
Completed
Trial end date:
2017-05-21
Target enrollment:
Participant gender:
Summary
This study comprises 2 cohorts, and in each cohort, the study will be conducted as an open-label add-on study. The purpose of the study is to investigate the pharmacokinetics of each substrate in concomitant administration of a single dose of the P-glycoprotein substrate digoxin (Cohort A) or the CYP3A4 substrate midazolam (Cohort B) during repeated administration of TRK-700 in healthy adult males.
Phase:
Phase 1
Details
Lead Sponsor:
Toray Industries, Inc
Treatments:
Digoxin
Midazolam